Form 8-K - Current report:
SEC Accession No. 0001576885-23-000056
Filing Date
2023-11-09
Accepted
2023-11-08 17:59:07
Documents
12
Period of Report
2023-11-05
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K abos-20231105.htm   iXBRL 8-K 26534
  Complete submission text file 0001576885-23-000056.txt   155565

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20231105.xsd EX-101.SCH 1901
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20231105_lab.xml EX-101.LAB 24833
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20231105_pre.xml EX-101.PRE 13043
6 EXTRACTED XBRL INSTANCE DOCUMENT abos-20231105_htm.xml XML 2809
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

EIN.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 231389461
SIC: 2836 Biological Products, (No Diagnostic Substances)